113 related articles for article (PubMed ID: 24882036)
21. Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery.
Cole H; Bryan D; Lancaster L; Mawas F; Vllasaliu D
Carbohydr Polym; 2018 Jun; 190():248-254. PubMed ID: 29628245
[TBL] [Abstract][Full Text] [Related]
22. Transport mechanism of doxorubicin loaded chitosan based nanogels across intestinal epithelium.
Feng C; Sun G; Wang Z; Cheng X; Park H; Cha D; Kong M; Chen X
Eur J Pharm Biopharm; 2014 May; 87(1):197-207. PubMed ID: 24316340
[TBL] [Abstract][Full Text] [Related]
23. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations.
Mahjub R; Radmehr M; Dorkoosh FA; Ostad SN; Rafiee-Tehrani M
Drug Dev Ind Pharm; 2014 Dec; 40(12):1645-59. PubMed ID: 24093431
[TBL] [Abstract][Full Text] [Related]
24. Stearic acid-g-chitosan polymeric micelle for oral drug delivery: in vitro transport and in vivo absorption.
Yuan H; Lu LJ; Du YZ; Hu FQ
Mol Pharm; 2011 Feb; 8(1):225-38. PubMed ID: 21138243
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models.
Sandri G; Bonferoni MC; Rossi S; Ferrari F; Gibin S; Zambito Y; Di Colo G; Caramella C
Eur J Pharm Biopharm; 2007 Jan; 65(1):68-77. PubMed ID: 16962751
[TBL] [Abstract][Full Text] [Related]
26. Transmucosal macromolecular drug delivery.
Prego C; García M; Torres D; Alonso MJ
J Control Release; 2005 Jan; 101(1-3):151-62. PubMed ID: 15588901
[TBL] [Abstract][Full Text] [Related]
27. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin.
Bai S; Thomas C; Ahsan F
J Pharm Sci; 2007 Aug; 96(8):2090-106. PubMed ID: 17286291
[TBL] [Abstract][Full Text] [Related]
28. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin.
Chen MC; Wong HS; Lin KJ; Chen HL; Wey SP; Sonaje K; Lin YH; Chu CY; Sung HW
Biomaterials; 2009 Dec; 30(34):6629-37. PubMed ID: 19767097
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of Eudragit® L100-coated chitosan-based nanoparticles for oral enoxaparin delivery.
Patriota YBG; Arruda IES; de Jesus Oliveira AC; de Oliveira TC; de Lemos Vasconcelos Silva E; Chaves LL; de Oliveira Silva Ribeiro F; da Silva DA; de La Roca Soares MF; Soares-Sobrinho JL
Int J Biol Macromol; 2021 Dec; 193(Pt A):450-456. PubMed ID: 34688680
[TBL] [Abstract][Full Text] [Related]
30. Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation.
Lian X; Dong J; Zhang J; Teng Y; Lin Q; Fu Y; Gong T
Int J Pharm; 2014 Dec; 477(1-2):399-407. PubMed ID: 25445521
[TBL] [Abstract][Full Text] [Related]
31. The efficiency and mechanism of N-octyl-O, N-carboxymethyl chitosan-based micelles to enhance the oral absorption of silybin.
Yin T; Zhang Y; Liu Y; Chen Q; Fu Y; Liang J; Zhou J; Tang X; Liu J; Huo M
Int J Pharm; 2018 Jan; 536(1):231-240. PubMed ID: 29162374
[TBL] [Abstract][Full Text] [Related]
32. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
Zhang X; Sun M; Zheng A; Cao D; Bi Y; Sun J
Eur J Pharm Sci; 2012 Apr; 45(5):632-8. PubMed ID: 22248882
[TBL] [Abstract][Full Text] [Related]
33. Effect of Glyceryl Monocaprylate-Modified Chitosan on the Intranasal Absorption of Insulin in Rats.
Gao M; Sun Y; Kou Y; Shen X; Huo Y; Liu C; Sun Z; Zhang X; Mao S
J Pharm Sci; 2019 Nov; 108(11):3623-3629. PubMed ID: 31356762
[TBL] [Abstract][Full Text] [Related]
34. A mechanistic based approach for enhancing buccal mucoadhesion of chitosan.
Meng-Lund E; Muff-Westergaard C; Sander C; Madelung P; Jacobsen J
Int J Pharm; 2014 Jan; 461(1-2):280-5. PubMed ID: 24291123
[TBL] [Abstract][Full Text] [Related]
35. Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
Feng C; Wang Z; Jiang C; Kong M; Zhou X; Li Y; Cheng X; Chen X
Int J Pharm; 2013 Nov; 457(1):158-67. PubMed ID: 24029170
[TBL] [Abstract][Full Text] [Related]
36. Preparation, optimization, and in-vitro/in-vivo/ex-vivo characterization of chitosan-heparin nanoparticles: drug-induced gelation.
Shahbazi MA; Hamidi M; Mohammadi-Samani S
J Pharm Pharmacol; 2013 Aug; 65(8):1118-33. PubMed ID: 23837580
[TBL] [Abstract][Full Text] [Related]
37. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs.
van der Merwe SM; Verhoef JC; Verheijden JH; Kotzé AF; Junginger HE
Eur J Pharm Biopharm; 2004 Sep; 58(2):225-35. PubMed ID: 15296951
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of Pluronic(®) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats.
Chen D; Xia D; Li X; Zhu Q; Yu H; Zhu C; Gan Y
Int J Pharm; 2013 Jun; 449(1-2):1-9. PubMed ID: 23583840
[TBL] [Abstract][Full Text] [Related]
39. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells.
Tahara K; Sakai T; Yamamoto H; Takeuchi H; Hirashima N; Kawashima Y
Int J Pharm; 2009 Dec; 382(1-2):198-204. PubMed ID: 19646519
[TBL] [Abstract][Full Text] [Related]
40. Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats.
Yang T; Mustafa F; Ahsan F
J Pharm Pharmacol; 2004 Jan; 56(1):53-60. PubMed ID: 14980001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
